Logo image of SPRB

SPRUCE BIOSCIENCES INC (SPRB) Stock Price, Quote, News and Overview

NASDAQ:SPRB - Nasdaq - US85209E1091 - Common Stock - Currency: USD

0.0786  -0.05 (-39.45%)

After market: 0.0788 +0 (+0.25%)

SPRB Quote, Performance and Key Statistics

SPRUCE BIOSCIENCES INC

NASDAQ:SPRB (4/28/2025, 8:00:02 PM)

After market: 0.0788 +0 (+0.25%)

0.0786

-0.05 (-39.45%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High0.87
52 Week Low0.08
Market Cap3.32M
Shares42.23M
Float37.45M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-12 2025-05-12/amc
IPO10-09 2020-10-09


SPRB short term performance overview.The bars show the price performance of SPRB in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

SPRB long term performance overview.The bars show the price performance of SPRB in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of SPRB is 0.0786 USD. In the past month the price decreased by -73.37%. In the past year, price decreased by -89.44%.

SPRUCE BIOSCIENCES INC / SPRB Daily stock chart

SPRB Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.56B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.18B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About SPRB

Company Profile

SPRB logo image Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company is headquartered in South San Francisco, California and currently employs 21 full-time employees. The company went IPO on 2020-10-09. The firm has acquired an exclusive worldwide license agreement for tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfilippo Syndrome Type B (MPS IIIB). The TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) with modified human insulin-like growth factor 2 via an amino acid linker. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. The firm's pipeline also includes Tildacerfont and Cortibon for the treatment of Major Depressive Disorder, SPR202 for the treatment of Congenital Adrenal Hyperplasia and SPR204 for the treatment of Post-Bariatric Hypoglycemia.

Company Info

SPRUCE BIOSCIENCES INC

611 Gateway Boulevard, Suite 740

South San Francisco CALIFORNIA 94104 US

CEO: Richard King

Employees: 22

Company Website: https://sprucebio.com/

Investor Relations: https://investors.sprucebiosciences.com/

Phone: 14156554168

SPRUCE BIOSCIENCES INC / SPRB FAQ

What is the stock price of SPRUCE BIOSCIENCES INC today?

The current stock price of SPRB is 0.0786 USD. The price decreased by -39.45% in the last trading session.


What is the ticker symbol for SPRUCE BIOSCIENCES INC stock?

The exchange symbol of SPRUCE BIOSCIENCES INC is SPRB and it is listed on the Nasdaq exchange.


On which exchange is SPRB stock listed?

SPRB stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for SPRUCE BIOSCIENCES INC stock?

10 analysts have analysed SPRB and the average price target is 1.53 USD. This implies a price increase of 1846.56% is expected in the next year compared to the current price of 0.0786. Check the SPRUCE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is SPRUCE BIOSCIENCES INC worth?

SPRUCE BIOSCIENCES INC (SPRB) has a market capitalization of 3.32M USD. This makes SPRB a Nano Cap stock.


How many employees does SPRUCE BIOSCIENCES INC have?

SPRUCE BIOSCIENCES INC (SPRB) currently has 22 employees.


Is SPRUCE BIOSCIENCES INC (SPRB) expected to grow?

The Revenue of SPRUCE BIOSCIENCES INC (SPRB) is expected to decline by -68.59% in the next year. Check the estimates tab for more information on the SPRB EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy SPRUCE BIOSCIENCES INC (SPRB) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does SPRUCE BIOSCIENCES INC (SPRB) stock pay dividends?

SPRB does not pay a dividend.


When does SPRUCE BIOSCIENCES INC (SPRB) report earnings?

SPRUCE BIOSCIENCES INC (SPRB) will report earnings on 2025-05-12, after the market close.


What is the Price/Earnings (PE) ratio of SPRUCE BIOSCIENCES INC (SPRB)?

SPRUCE BIOSCIENCES INC (SPRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.28).


What is the Short Interest ratio of SPRUCE BIOSCIENCES INC (SPRB) stock?

The outstanding short interest for SPRUCE BIOSCIENCES INC (SPRB) is 1.37% of its float. Check the ownership tab for more information on the SPRB short interest.


SPRB Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

SPRB Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to SPRB. SPRB has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SPRB Financial Highlights

Over the last trailing twelve months SPRB reported a non-GAAP Earnings per Share(EPS) of -1.28. The EPS decreased by -1.59% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -117.31%
ROE -184.02%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-137.5%
Sales Q2Q%-75.86%
EPS 1Y (TTM)-1.59%
Revenue 1Y (TTM)-51.31%

SPRB Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 50% to SPRB. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 54.58% and a revenue growth -68.59% for SPRB


Ownership
Inst Owners43.66%
Ins Owners11.57%
Short Float %1.37%
Short Ratio0.33
Analysts
Analysts50
Price Target1.53 (1846.56%)
EPS Next Y54.58%
Revenue Next Year-68.59%